Illumina, Inc. reported $4.49B of revenue over the trailing twelve months, +4.9% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.49B (to Q2 2026). Net Income: $825M, trailing twelve months to Q2 2026. Free Cash Flow: $931M, trailing twelve months to Q2 2026. Op Margin: 20%, trailing twelve months to Q2 2026.

ILMNIllumina, Inc.

HealthcareUSD

$224.91

$91.0052 weeks$225.01

ILMN as reported

Illumina, Inc. reported $4.49B of revenue over the trailing twelve months, +4.9% on the year before. 11 reported series are charted on this page, each one as filed.

$4.49B

Revenue, trailing twelve months · to Q2 2026 · +4.9% against the twelve months before

Net Income: $825M
Net Income · −34% year on year · trailing twelve months to Q2 2026
Free Cash Flow: $931M
Free Cash Flow · −9.7% year on year · trailing twelve months to Q2 2026
Op Margin: 20%
Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for ILMN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.49B	+4.9%	Q2 2026
Net Income	$825M	−34%	Q2 2026
EPS	$5.36	−32%	Q2 2026
Gross Margin	66%	n/a	Q2 2026
Op Margin	20%	n/a	Q2 2026
Net Margin	18%	n/a	Q2 2026
ROE	30%	n/a	Q2 2026
ROA	12%	n/a	Q2 2026
ROIC	34%	n/a	Q2 2026
Free Cash Flow	$931M	−9.7%	Q2 2026
P/E	42.0	n/a	today